Literature DB >> 27142783

Clinical research in neonates and infants: Challenges and perspectives.

Raffaele Coppini1, Sinno H P Simons2, Alessandro Mugelli3, Karel Allegaert4.   

Abstract

To date, up to 65% of drugs used in neonates and infants are off-label or unlicensed, as they were implemented in clinical care without the usual regulatory phases of pharmacological drug development. Pharmacotherapy in this age group is still mainly based on the individual clinical expertise of specialized pediatricians. Pharmacological trials involving neonates are indeed more difficult to perform: appropriate dosing is hampered by the rapid physiological changes occurring at this stage of development, and the selection of proper end-points and biomarkers is complicated by the limited knowledge of the pathophysiology of the specific diseases of infancy. Moreover, there are many ethical challenges in planning and conducting drug studies in pediatric patients (especially in newborns and infants). In the current review, we address some challenges and discuss possible perspectives to stimulate scientific and clinical pharmacological research in neonates and infants. We hereby aim to illustrate the add on value of the regulatory framework for model-based neonatal medicinal development currently used in Europe and the United States. We provide several examples of successful recent pharmacological trials performed in neonates and infants. In these examples, success was ensured by the implementation of specific pharmacokinetic assessments, thanks to accurate drug dosing achieved with a combination of dose validation, population pharmacokinetics and mathematical models of drug clearance and distribution; moreover, age-specific pharmacodynamics was considered via appropriate evaluations of drug efficacy with end-points adapted to the peculiar pathophysiology of diseases in this age group. These "pharmacological" challenges add to the ethical challenges that are always present in planning and conducting clinical studies in neonates and infants and support the opinion that clinical research in pediatrics should be evaluated by ad hoc ethical committees with specific expertise.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Aminoglycoside; Beta-blockers; Paracetamol; Pediatrics; Pharmacodynamics; Pharmacokinetics

Mesh:

Substances:

Year:  2016        PMID: 27142783     DOI: 10.1016/j.phrs.2016.04.025

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  9 in total

Review 1.  Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature.

Authors:  Patrick C Donnelly; Rebecca M Sutich; Ryan Easton; Oluwatunmise A Adejumo; Todd A Lee; Latania K Logan
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

Review 2.  Extent, reasons and consequences of off-labeled and unlicensed drug prescription in hospitalized children: a narrative review.

Authors:  Wasim Shuib; Xin-Yin Wu; Fang Xiao
Journal:  World J Pediatr       Date:  2021-06-02       Impact factor: 2.764

3.  Drug Clearance in Neonates: A Combination of Population Pharmacokinetic Modelling and Machine Learning Approaches to Improve Individual Prediction.

Authors:  Bo-Hao Tang; Zheng Guan; Karel Allegaert; Yue-E Wu; Efthymios Manolis; Stephanie Leroux; Bu-Fan Yao; Hai-Yan Shi; Xiao Li; Xin Huang; Wen-Qi Wang; A-Dong Shen; Xiao-Ling Wang; Tian-You Wang; Chen Kou; Hai-Yan Xu; Yue Zhou; Yi Zheng; Guo-Xiang Hao; Bao-Ping Xu; Alison H Thomson; Edmund V Capparelli; Valerie Biran; Nicolas Simon; Bernd Meibohm; Yoke-Lin Lo; Remedios Marques; Jose-Esteban Peris; Irja Lutsar; Jumpei Saito; Jacobus Burggraaf; Evelyne Jacqz-Aigrain; John van den Anker; Wei Zhao
Journal:  Clin Pharmacokinet       Date:  2021-05-27       Impact factor: 5.577

4.  Large differences in neonatal drug use between NICUs are common practice: time for consensus?

Authors:  Robert B Flint; Floor van Beek; Peter Andriessen; Luc J Zimmermann; Kian D Liem; Irwin K M Reiss; Ronald de Groot; Dick Tibboel; David M Burger; Sinno H P Simons
Journal:  Br J Clin Pharmacol       Date:  2018-04-17       Impact factor: 4.335

Review 5.  Neonatal pharmacology and clinical implications.

Authors:  Antonio Ruggiero; Anna Ariano; Silvia Triarico; Michele Antonio Capozza; Pietro Ferrara; Giorgio Attinà
Journal:  Drugs Context       Date:  2019-10-14

6.  A Neonatal Murine Escherichia coli Sepsis Model Demonstrates That Adjunctive Pentoxifylline Enhances the Ratio of Anti- vs. Pro-inflammatory Cytokines in Blood and Organ Tissues.

Authors:  Esther M Speer; Elizabet Diago-Navarro; Lukasz S Ozog; Mahnoor Raheel; Ofer Levy; Bettina C Fries
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

7.  Guideline for the management of pediatric off-label use of drugs in China (2021).

Authors:  Min Meng; Enmei Liu; Bo Zhang; Quan Lu; Xiaobo Zhang; Bin Ge; Ye Wu; Li Wang; Mo Wang; Zhengxiu Luo; Ziyu Hua; Xiaoling Wang; Wei Zhao; Yi Zheng; Xinan Wu; Ruiling Zhao; Wenbo Meng; Li Xiang; Gang Wang; Yuntao Jia; Yongchuan Chen; Xiaoyan Dong; Lina Hao; Chengjun Liu; Meng Lv; Xufei Luo; Yunlan Liu; Quan Shen; Wenjuan Lei; Ping Wang; Yajia Sun; Juanjuan Zhang; Ling Wang; Ruobing Lei; Tianchun Hou; Bo Yang; Qiu Li; Yaolong Chen
Journal:  BMC Pediatr       Date:  2022-07-23       Impact factor: 2.567

8.  Pharmacometric approach to assist dosage regimen design in neonates undergoing therapeutic hypothermia.

Authors:  Saikumar Matcha; Elstin Anbu Raj; Ramya Mahadevan; Arun Prasath Raju; V Rajesh; Leslie Edward Lewis; Surulivelrajan Mallayasamy
Journal:  Pediatr Res       Date:  2021-09-07       Impact factor: 3.953

9.  Simultaneous quantification of fentanyl, sufentanil, cefazolin, doxapram and keto-doxapram in plasma using liquid chromatography-tandem mass spectrometry.

Authors:  Robert B Flint; Soma Bahmany; Bart C H van der Nagel; Birgit C P Koch
Journal:  Biomed Chromatogr       Date:  2018-06-12       Impact factor: 1.902

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.